Γιατί JUVÉDERM® IT;

ΠΑΡΑΠΟΜΠΕΣ

1. Allergan. DOF INT/0771/2016(2). Juvéderm is the world’s leading HA brand. Feb 2019.
2. Hee CK et al. Dermatol Surg. 2015;41(Suppl 1):S373–81.
3. Raspaldo H. J Cos Laser Ther. 2008;10:134–142.
4. Eccleston D and Murphy DK. Clin Cosmet Investig Dermatol. 2012;5:167–72.
5. Juvéderm® VOLIFT with lidocaine. 73652JT10. Revision 2019-09-09 (v0.1)
6. Juvéderm® VOLUMA with lidocaine. 73650JT10. Revision 2019-09-09 (v0.1
7. Juvéderm® VOLBELLA with lidocaine DFU. 73363JS10. Revision 2020-07-10.
8. Juvéderm® ULTRA XC PLUS DFU 73660RX10. Revision 2019-09-09. (v0.2).
9. Beer K. Dermatol Clin. 2009;27(4):427–32.
10. De Maio M and Loghem J. Beauty Through Science 2012. International Aesthetics
11. Juvéderm® VOLITE with lidocaine. 73655JT10. Revision 2019-09-09 (v0.1)
12. Juvéderm® VOLUX. 73651JT10. Revision 2019-09-09 (v0.1)
13. Juvéderm® ULTRA XC PLUS DFU 73660RX10. Revision 2019-09-09. (v0.2).
14. Juvéderm® ULTRA 2. 73661JT10. Revision 2019-09-09 (v0.1)
15. Juvéderm® ULTRA 3. 73662JT10. Revision 2019-09-09 (v0.1)
16. Juvéderm® ULTRA 4. 73663JT10. Revision 2019-09-09 (v0.1)
17. Allergan. Data on File. INT/0683/2017. Global Aesthetics Market Study. Aug 2017.
18. Stephens H. 2000. Allergan’s first fifty years. Lyme, Conn: Greenwich Pub. Group.
19. Goodman GJ, et al. Plast Reconstr Surg. 2015;136:139–48S
20. Brandt FS and Cazzaniga A. Clin Interv Aging. 2008;3(1):153–59.
21. Allemann IB and Baumann L. Clin Interv Aging. 2008;3(4):629–34.
22. Borelli C and Berneburg M. JDDG. 2010;8:326-30.
23. Fischer TC. J Cos Derm. 2010;9:291–96.
24. Jones D and Murphy DK. Dermatol Surg. 2013;39:111.
25. Allergan. Unpublished Data. INT/0297/2017. Juvéderm® VOLITE Clinical Study (V12-001), 9 months topline summary. Apr 2017.
26. Allergan. Data on File. INT/0773/2016(1). Juvéderm® VOLITE B without lidocaine. Sep 2018.
27. Carruthers A et al. Am Soc Dermatol Surg. 2008;34:167–72.